$175.74
0.19% yesterday
Nasdaq, Nov 20, 10:09 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$175.74
+40.89 30.32% 1M
+64.72 58.30% 6M
+52.59 42.70% YTD
+56.50 47.38% 1Y
+26.88 18.06% 3Y
+32.64 22.81% 5Y
+31.81 22.10% 10Y
+158.01 891.20% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.34 0.19%

New AI Insights on Jazz Pharmaceuticals Plc Insights AI Insights on Jazz Pharmaceuticals Plc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$10.7b
Enterprise Value
$14.0b
Net debt
$3.3b
Cash
$2.0b
Shares outstanding
60.7m
Valuation (TTM | estimate)
P/E
negative | 32.8
P/S
2.6 | 2.5
EV/Sales
3.4 | 3.3
EV/FCF
11.3
P/B
2.7
Financial Health
Equity Ratio
34.1%
Return on Equity
13.7%
ROCE
5.0%
ROIC
2.7%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$4.2b | $4.3b
EBITDA
$1.1b | $797.0m
EBIT
$453.9m | $751.1m
Net Income
$-368.5m | $326.5m
Free Cash Flow
$1.2b
Growth (TTM | estimate)
Revenue
4.1% | 5.8%
EBITDA
-17.1% | -41.1%
EBIT
-35.5% | 3.4%
Net Income
-179.6% | -41.7%
Free Cash Flow
12.5%
Margin (TTM | estimate)
Gross
88.5%
EBITDA
26.4% | 18.5%
EBIT
10.9%
Net
-8.9% | 7.6%
Free Cash Flow
29.8%
More
EPS
$-6.0
FCF per Share
$20.4
Short interest
9.7%
Employees
3k
Rev per Employee
$1.5m
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
92%
Hold
8%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,158 4,158
4% 4%
100%
- Direct Costs 478 478
13% 13%
12%
3,679 3,679
3% 3%
88%
- Selling and Administrative Expenses 1,772 1,772
28% 28%
43%
- Research and Development Expense 809 809
6% 6%
19%
1,098 1,098
17% 17%
26%
- Depreciation and Amortization 644 644
4% 4%
15%
EBIT (Operating Income) EBIT 454 454
36% 36%
11%
Net Profit -368 -368
180% 180%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
2 days ago
DUBLIN , Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m.
Positive
Seeking Alpha
3 days ago
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance support its current double-digit billion valuation. Key risks include upcoming patent expiries, new competition for Xywav, and uncertainty around long-term profitability and revenue replacement.
Positive
Seeking Alpha
3 days ago
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication repres...
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today